http://opendata.unex.es/recurso/educacion/universidad/personal/cece619136b0b5c9c153661ab9f5bdf8-adrian-llerena-ruiz
Relations
- teach:teacherOf
- ou:tienePublicacion
- 4th ESPT Conference: Pharmacogenomics and personalized medicine - Research progress and clinical implementation
- 4th ESPT summer school: Precision medicine and personalised health
- A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy
- A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? “Do Not Misuse Social Capital in the Age of Consortia Ethics”
- A PVC-graphite composite electrode for electroanalytical use. Preparation and some applications
- A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
- A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
- A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
- A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
- A tribute to José María (Chema) Cantú
- ABCB1 gene polymorphisms and violent suicide attempt among survivors
- ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: A case control study
- Acetylator polymorphism in Parkinson's disease
- Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
- An Appeal to the Global Health Community for a Tripartite Innovation: An essential Diagnostics List, health in All Policies, and see-Through 21<sup>st</sup> Century Science and Ethics
- An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
- An Open Letter in Support of Transformative Biotechnology and Social Innovation: SANKO University Innovation Summit in Medicine and Integrative Biology, Gaziantep, Turkey, May 5-7, 2016
- An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels
- An update on HLA alleles associated with adverse drug reactions
- Analysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios
- Ancestromics
- Ancestromics
- Antibiotic use in 3 European university hospitals
- Antipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
- Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
- Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs)
- Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
- Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
- Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
- Bernard lerer: Recipient of the 2014 inaugural werner kalow responsible innovation prize in global omics and personalized medicine (pacific rim association for clinical pharmacogenetics)
- CPPM 2013 onward: Building a socio-technical GPS for global personalized medicine - A welcome to editors-in-chief Adrián LLerena (Spain) and Ross A. McKinnon (Australia)
- CPPM onward and upward: Global personalized medicine guided by responsible innovation
- CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
- CYP2C9 gene and susceptibility to major depressive disorder
- CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
- CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
- CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters.
- CYP2D6 and the severity of suicide attempts
- CYP2D6 ethnic variability in hispanics
- CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico
- CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
- CYP2D6 genetic polymorphism and psychiatry patients' hospitalization period
- CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
- CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
- CYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies
- CYP2D6 polymorphism and mental and personality disorders in suicide attempters
- CYP2D6 polymorphism in patients with eating disorders
- CYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
- CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
- CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
- CYP2D6 variation, behaviour and psychopathology: Implications for pharmacogenomics-guided clinical trials
- CYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
- CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
- CYP450 genotype and pharmacogenetic association studies: A critical appraisal
- Can the CEIBA cocktail designed for human cytochrome P450 enzymes be used in the rat for drug interaction studies?
- Carbamazepine adverse drug reactions
- Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
- Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update
- Clinical drug-drug interactions: Focus on venlafaxine
- Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
- Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
- Clinical pharmacology of drug metabolism and drug interactions: Clinical, interethnical and regulatory aspects
- Clinical use of pre-emptive pharmacogenetic programmes
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
- Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient
- Concordance of phenotype and genotype for CYP2D6 [1]
- Current insights into interethnic variability in testicular cancers: Population pharmacogenetics, clinical trials, genetic basis of chemotherapyinduced toxicities and molecular signal transduction
- Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction
- Cytochrome P450 genetic polymorphisms of Mexican indigenous populations
- DEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
- Debrisoquin and mephenytoin hydroxylation phenotypes and CΥP2D6 genotype in patients treated with neuroleptic and antidepressant agents
- Debrisoquin oxidation polymorphism in a Spanish population
- Debrisoquine oxidation phenotype in psychiatric patients.
- Debrisoquine oxidation in schizophrenic patients treated with neuroleptics
- Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection
- Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
- Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
- Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions
- Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
- Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
- Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis
- Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
- Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.
- Drug-drug interactions. Things to do in pain management
- Eating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
- Editorial
- Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
- Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
- Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations
- Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment
- Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
- Erratum: Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment (Molecular Psychiatry, (2017), 22, 8, (1155-1163), 10.1038/mp.2016.204)
- Erratum: Schizophrenia and tobacco smoking in a Spanish psychiatric hospital (Schizophrenia Research (2002) 58 (323-327) PII: S09209964010032)
- Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans
- Evaluating a newly developed pharmacogenetic array: Screening in a Spanish population
- Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
- Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
- Exposiciones preparadas por alumnos: Una experiencia didáctica
- Extending automorphisms to the rational fractions field
- Farmacogenética y farmacogenómica
- Farmacogenética y farmacogenómica
- First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma
- Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.
- Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
- Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
- Genetic factors in the metabolism of haloperidol.
- Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative
- Genetic variability of CYP2C9∗2 and CYP2C9∗3 in seven indigenous groups from Mexico
- Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
- Genomic Medicine in Developing Countries and Resource-Limited Environments
- Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina
- Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
- Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
- Hepatic actinomycosis
- High frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
- High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
- High frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
- High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
- High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
- High risk of polydipsia and water intoxication in schizophrenia patients
- High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
- Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen
- Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis
- Impact of cytochrome P450 genes on suicide attempt and risk
- Implementation of pharmacogenetics in primary care
- Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
- Increased use of second generation antipsychotic drugs in primary care: Potential relevance for hospitalizations in schizophrenia patients
- Influence of CYP2D6 deletion, multiplication, -1584C→G, 31G→A and 2988G→A gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos
- Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico
- Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population
- Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
- Interaction between prajmaline and metoprotol: a possible pharmacogenetic explanation
- Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
- Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
- Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
- Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem
- Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
- Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
- Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
- Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations
- Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
- Leaders in pharmacogenetics: Urs Albert Meyer
- Lessons from Cuba for global precision medicine: CYP2D6 genotype is not a robust predictor of CYP2D6 ultrarapid metabolism
- Liver enzyme abnormalities during antipsychotic treatment: A case report of risperidone-associated hepatotoxicity
- Losartan hydroxylation phenotype in an Ecuadorian population: Influence of CYP2C9 genetic polymorphism, habits and gender
- Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
- Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
- MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers
- Manual de utilización de la vía subcutánea: perfusión subcutánea continua y control de síntomas en el enfermo en situación terminal
- Metabolic phenotype prediction from genotyping data: A bottleneck for the implementation of pharmacogenetics in drug development and clinical practice
- Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe
- Multiple adverse drug reactions and genetic polymorphism testing
- Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach
- Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
- New perspectives in personalised medicine for ethnicity in cancer: Population pharmacogenomics and pharmacometrics
- Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285
- News in DMPT: Leaders in Pharmacogenetics Section
- No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients [2]
- Optimizar la terapéutica famacológica en ancianos
- Optimizing pharmacologic therapy for the elderly
- Oxidative polymorphism of debrisoquine in Parkinson's disease
- Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.
- Pharmacogenetic Sex-Specific Effects of Methotrexate Response in Patients with Rheumatoid Arthritis
- Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response
- Pharmacogenetic research activity in Central America and the Caribbean: A systematic review
- Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes
- Pharmacogenetic studies of suicide: Potential relevance of main polymorphic CYPs and ABCB1
- Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America
- Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (Non-)genetic factors
- Pharmacogenetics and ethnicity: dr. José María Cantú award announcement
- Pharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
- Pharmacogenetics in Central American healthy volunteers: Interethnic variability
- Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
- Pharmacogenetics of Antidepressant Drug Metabolism and Its Clinical Implications
- Pharmacogenetics of adverse reactions to antiepileptic drugs
- Pharmacogenetics of clinical response to risperidone
- Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
- Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial
- Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients
- Pharmacogenetics research in Brazil: a systematic review
- Pharmacogenetics: ethnicity, treatment and health in Latin American populations
- Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies
- Pharmacogenomic information in drug labels: European Medicines Agency perspective
- Pharmacogenomics and personality: Role of CYP2D6 and implications for psychopathology
- Pharmacogenomics and personalized medicine in clinical practice
- Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools Deans of Education
- Pharmacogenomics education in medical and pharmacy schools: Conclusions of a global survey
- Pharmacogenomics in pain treatment
- Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
- Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
- Pharmacological compliance in the treatment of arterial hypertension. A review of studies published between 1975 and 2011
- Poisoning by organophosphate insecticides. Epidemiology and prevention
- Polimorfismo acetilador en el cancer de pulm6n
- Polymorphic oxidation of debrisoquine in lung cancer patients
- Polymorphic oxidation of debrisoquine in women with breast cancer
- Polymorphic oxidation of debrisoquine in bladder cancer
- Population genetics of PDE4B (phosphodiesterase-4B) in neglected Native Americans: Implications for cancer pharmacogenetics
- Population pharmacogenetics and global health
- Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014)
- Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen
- Preface
- Preface
- Preface
- Preface
- Present status and perspective of pharmacogenetics in Mexico
- Prevalence of polydipsia and water intoxication in psychiatric inpatients
- Prevalencia de polidipsia e intoxicacion por agua en pacientes psiquiatricos hospitalizados
- Progress in pharmacogenetics: Consortiums and new strategies
- Psychotropic drug use in non-psychiatric departments of three European university hospitals
- QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
- QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
- QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
- Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy
- Real-World Clinical Characterization of Subjects With Depression Treated With Antidepressant Drugs Focused on (Non-)Genetic Factors, Pharmacokinetics, and Clinical Outcomes: GnG-PK/PD-AD Study
- Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods
- References used in a Drug Information Centre
- Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
- Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers
- Relationship between clozapine plasma levels and withdrawal symptoms
- Relationship between personality and debrisoquine hydroxylation capacity: Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
- Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers
- Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers
- Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients
- Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients
- Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
- Relevance of CYP2D6 for risperidone pharmacokinetics, pharmacodynamics and adverse reactions.
- Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
- Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
- Relevance of personalized medicine for improving traditional medicine
- Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
- Reproducibility over time of the urinary diclofenac/4′-OH diclofenac ratio among different CYP2C9 genotypes
- Reproducibility over Time of Mephenytoin and Debrisoquine Hydroxylation Phenotypes
- Research Highlights: novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity.
- Schizophrenia and herpes simplex hominis type I virus
- Schizophrenia and tobacco smoking in a Spanish psychiatric hospital [1]
- Schizophrenia and tobacco smoking in a Spanish psychiatric hospital
- Schizophrenia stigma among medical and nursing undergraduates [2]
- Setas. Intoxicación, tratamiento y prevención
- Simultaneous determination of cytochrome P450 oxidation capacity in humans: A review on the phenotyping cocktail approach
- Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: The potential value of the PEPs study
- Study of debrisoquine polymorphism in a sample of the Cuban population
- Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards
- Subcutaneous drug administration. Indications for the use in terminal patients
- Subtyping undergraduate women along dietary restraint and negative affect
- Success stories in genomic medicine from resource-limited countries
- The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What’s next? An urgent clinical unmet need for patients
- The psychostimulant khat (Catha edulis) inhibits CYP2D6 enzyme activity in humans
- The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
- The social gathering of the Latin American program of science and technology for development
- The underlying traits of the Karolinska Scales of Personality (KSP)
- The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
- Therapeutic drug monitoring of fluoxetine, norfluoxetine and paroxetine: A new tool based on microextraction by packed sorbent coupled to liquid chromatography
- Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
- Third Santorini conference pharmacogenomics workshop report: Pharmacogenomics at the crossroads: What else than good science will be needed for the field to become part of Personalized Medicine?
- To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population
- Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications
- Toward more transparent and reproducible omics studies through a common metadata checklist and data publications
- Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a science peace corps - An open letter to world leaders
- Tratamiento quirúrgico en un hamartoma combinado de retina y epitelio pigmentario
- Términos farmacogenéticos
- Use of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
- Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
- VEGF-related polymorphisms identified by GWAS and risk for major depression
- Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers
- Water pipe (Shisha, Hookah, Arghile) Smoking and Secondhand Tobacco Smoke Effects on CYP1A2 and CYP2A6 Phenotypes as Measured by Caffeine Urine Test
- What is the future of pharmacogenomics in pain management?
- Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes
- [Ibero-American Program of Science and Technology for Development].
- ou:perteneceAGrupoInvestigacion
- ou:imparteDocenciaEnArea
- ou:adscritoACentro
- ou:adscritoADepartamento
Inverse Relations
Inverse Blank Nodes
